WCLC Sydney Octobre 2013
Communications de BREC
[pdf]WCLC2013-PresentationSlidesTEMPLATECC[/pdf]
Abstract Rebiopsie accepté en mini présentation orale
Session: NSCLC – Targeted Therapies III
Mon, October 28, 2013- 4:15 – 5:45
Feasibility and clinical impact of re-biopsy in advanced non-small cell lung cancer: a prospective multicentric study in real world setting (GFPC study 12-01)
[pdf]rebiop__abstract_submission[/pdf]
Abstract d’ESOGIA accepté en présentation orale de 10 min
Session: NSCLC – Chemotherapy II
Tue, October 29, 2013: Bayside Auditorium A, 10:30 – 12:00
Phase III, randomized, multicenter study comparing in elderly patients (≥70 years) with stage IV non small-cell lung cancer (NSCLC) a standard strategy of treatment allocation (carboplatin based bi-therapy or monotherapy with docetaxel) based on performance status (PS) and age with an experimental strategy allocating the same chemotherapies or best supportive care (BSC) according to a comprehensive geriatric assessment (CGA) – Study ESOGIA-GFPC-GECP 08-02
[word]Abstract V3 Sydney[/word]
Abstract EURTAC accepté présentation orale
Session: NSCLC – Targeted Therapies III
Tue, October 29, 2013- 10:30 – 12:00
Cost-utility analysis of first-line treatment with erlotinib versus chemotherapy in EGFR-mutant advanced non-small-cell lung cancer (NSCLC): economic analysis of EURTAC trial.
[pdf]EURTAC submission [/pdf]
Abstract TARSEQ accepté en Poster
P2.09 – Poster Session 2 – Chemotherapy,
October 29, 2013 9:30 – 16:30
Randomized non comparative multicenter phase II study of sequential erlotinib with docetaxel versus docetaxel alone in patients with non small cell lunger cancer (NSCLC) after failure of first line chemotherapy (TARSEQ): a GFPC 10.02 study.
[pdf]Abstract 972 tarseq V9[/pdf]
Abstract de RACCOSA accepté en Poster
P2.10 – Poster Session 2 – Combined Modality
Tue, October 29, 2013: Exhibit Hall, 09:30 – 16:30
Phase II study of concurrent chemo-radiotherapy (CRT) with weekly cisplatinum plus oral vinorelbine in fit elderly patients with nonresectable locally advanced non-small-cell lung cancer (NSCLC) assessed by Standardized Geriatric Assessment (RACCOSA, GFPC 08-06 study) : interim analysis.
[word]Abstract IASCLC VF 06-2013[/word]
Abstract accepté en Poster
P3.09 – Poster Session 3 – Chemotherapy
Wed, October 30, 2013 :
Impact of a Comprehensive Geriatric Assessment on management strategies in elderly patients with advanced no small cell lung cancer (NSCLC): a polled analysis of two phase 2 prospective study of the GFPC group
[word]abstract_CGA_WCLC_Borget[/word]
Abstract accepté en Poster
P2.24 – Poster Session 2 – Supportive Care
Tuesday, October 29, 2013
Renal failure is the first cause of double maintenance (bevacizumab + pemetrexed) discontinuation for toxicity in real world setting
[word]M Sassier Abs 2491 – Toxaval – WCLC 2013[/word]
Abstract accepté en poster
Mon, October 28, 2013
Clinical features and current management of malignant pleural mesothelioma in France. (ECOMESO -The GFPC 0804 study)
[pdf]Ecomeso_abstract_lung_2013 cccr[/pdf]